Document is current
Any future updates will be listed below
-
Authors
Takeji, Yasuaki
Taniguchi, Tomohiko
Morimoto, Takeshi
Shirai, Shinichi
Kitai, Takeshi
Tabata, Hiroyuki
Ohno, Nobuhisa
Murai, Ryosuke
Osakada, Kohei
Murata, Koichiro
Nakai, Masanao
Tsuneyoshi, Hiroshi
Tada, Tomohisa
Amano, Masashi
Watanabe, Shin
Shiomi, Hiroki
Watanabe, Hirotoshi
Yoshikawa, Yusuke
Nishikawa, Ryusuke
Obayashi, Yuki
Yamamoto, Ko
Toyofuku, Mamoru
Tatsushima, Shojiro
Kanamori, Norio
Miyake, Makoto
Nakayama, Hiroyuki
Nagao, Kazuya
Izuhara, Masayasu
Nakatsuma, Kenji
Inoko, Moriaki
Fujita, Takanari
Kimura, Masahiro
Ishii, Mitsuru
Usami, Shunsuke
Nakazeki, Fumiko
Togi, Kiyonori
Inuzuka, Yasutaka
Ando, Kenji
Komiya, Tatsuhiko
Ono, Koh
Minatoya, Kenji
Kimura, Takeshi
,
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 14 October 2024
First Online: 28 November 2024
Declarations
:
: K. Ono and K. Minatoya are members of Circulation Journal’s Editorial Team. S.S. reports clinical proctoring for Edwards Life Science, Medtronic, and Abbott Vascular. H.S. reports receiving personal fees from Abbott Vascular, Boston Scientific, and Daiichi Sankyo. T.M reports receiving lecturer fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray and manuscript fees from Bristol-Myers Squibb and Kowa, as well as being on the advisory board for Sanofi. T. Kimura reports being on the advisory board for Abbott Vascular and receiving grants from Edwards Lifescience, Daiichi Sankyo, Takeda Pharmaceutical, Bayer, Otsuka Parmaceutical, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, Kowa, Abiomed, Japan Academic Research Forum, NIPRO, W.L. Gore & Associates G.K., RPM Co., Ltd., CSL Behring, Pfizer R&D Japan G.K., and EP- CRSU Co., Ltd; and honoraria from MSD, Eisai, Edwards Lifescience, Ono Pharmaceutical, Tsumura, Medical Review, Kowa, Sanofi, Pharmaceuticals and Medical Devices Agency, Bristol-Myers Squibb, Boston Scientific, Lifescience, Toray, Astellas Amgen Biopharma, Astellas, AstraZeneca, OrbusNeich, MSD Life Science Foundation, Public Health Research Foundation, Chugai Pharmaceutical, Japan Society for the Promotion of Science, Interscience, Philips, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Terumo, Novartis Pharma, HeartFlow Japan G.K., and CROSSCO Co. The remaining authors have no conflicts of interest to disclose.
: The present study was approved by Kyoto University Graduate School and Faculty of Medicine Ethics Committee, Reference number: R1501.
